Skip to Main Content

Someone needs to tell Michel Vounatsos that he suffers from a terrible case of tin ear syndrome.

At a time when many Americans are increasingly angry over the cost of medicines, the Biogen chief executive last June slapped a $56,000 price tag on its newly approved Alzheimer’s treatment.


Ever since, nothing but scandal has enveloped him and the company he runs. Moreover, he has further harmed an industry that often struggles — sometimes, for good reason — to convince the public it is on the side of the angels.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.